Imatinib works by blocking the tyrosine kinase activity of the BCR-ABL protein, which is essential for the proliferation of cancer cells. By inhibiting this enzyme, imatinib effectively halts the growth and spread of cancerous cells. This specific action makes imatinib a targeted therapy, reducing damage to normal, healthy cells.
